Topics:
Genitourinary Cancers • Prostate Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Duke • NCI-CCC GU Tumor Board Question • Duke GU Tumor Board
How does the FDA approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) change how you image and manage patients with metastatic castrate-resistant prostate cancer?
When do you order PSMA PET? Will you preferably order Locametz (gallium Ga 68 gozetotide) PET?
Answer from: Medical Oncologist at Academic Institution
The FDA approval of Pluvicto was a welcome addition to a growing list of treatments for patients with mCRPC. Logistical issues with administration have slowed the routine implementation of this therapy in the US. In terms of imaging, a PSMA-PET is required prior to the administration of Pluvicto to ...
Sign in or Register to read more